AbbVie: Humira Competition Has Gone ‘Exceptionally Well’ For Us

Biosimilars Struggle To Capture Large Volumes In US; Brand Erosion Is Mainly Price

With adalimumab biosimilars slow to capture market share from Humira in the US, AbbVie says that erosion for the top-selling brand is continuing to go “exceptionally well” for the originator.

AbbVie On Phone With Data Sheets, Spreadsheets, Graphs
AbbVie outlines the latest trends in US Humira erosion • Source: Shutterstock

Biosimilar competition to Humira (adalimumab) in the US has gone “exceptionally well” for originator AbbVie, company management has outlined, nearly a year since the launch of the first rival to the top-selling brand.

Speaking at the annual J.P. Morgan Healthcare Conference in January, AbbVie president and chief operating officer Robert Michael said the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.